全文获取类型
收费全文 | 21118篇 |
免费 | 1843篇 |
国内免费 | 488篇 |
专业分类
耳鼻咽喉 | 58篇 |
儿科学 | 839篇 |
妇产科学 | 460篇 |
基础医学 | 2301篇 |
口腔科学 | 187篇 |
临床医学 | 2030篇 |
内科学 | 3975篇 |
皮肤病学 | 315篇 |
神经病学 | 3977篇 |
特种医学 | 703篇 |
外国民族医学 | 2篇 |
外科学 | 1831篇 |
综合类 | 1961篇 |
一般理论 | 6篇 |
预防医学 | 1738篇 |
眼科学 | 179篇 |
药学 | 1497篇 |
2篇 | |
中国医学 | 287篇 |
肿瘤学 | 1101篇 |
出版年
2024年 | 14篇 |
2023年 | 411篇 |
2022年 | 426篇 |
2021年 | 791篇 |
2020年 | 860篇 |
2019年 | 793篇 |
2018年 | 725篇 |
2017年 | 759篇 |
2016年 | 636篇 |
2015年 | 686篇 |
2014年 | 1217篇 |
2013年 | 1413篇 |
2012年 | 1017篇 |
2011年 | 1084篇 |
2010年 | 935篇 |
2009年 | 989篇 |
2008年 | 1041篇 |
2007年 | 935篇 |
2006年 | 907篇 |
2005年 | 792篇 |
2004年 | 696篇 |
2003年 | 665篇 |
2002年 | 585篇 |
2001年 | 495篇 |
2000年 | 441篇 |
1999年 | 409篇 |
1998年 | 341篇 |
1997年 | 321篇 |
1996年 | 268篇 |
1995年 | 340篇 |
1994年 | 272篇 |
1993年 | 229篇 |
1992年 | 247篇 |
1991年 | 205篇 |
1990年 | 175篇 |
1989年 | 164篇 |
1988年 | 135篇 |
1987年 | 107篇 |
1986年 | 124篇 |
1985年 | 174篇 |
1984年 | 145篇 |
1983年 | 86篇 |
1982年 | 89篇 |
1981年 | 80篇 |
1980年 | 57篇 |
1979年 | 42篇 |
1978年 | 30篇 |
1977年 | 22篇 |
1976年 | 25篇 |
1975年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Lei Qi Mingxing Wang Yuehui Jia Yuanyuan Wang Liangfang Xue Linlin Du Shuxiu Hao Shengqi Su Ruixiang Wang Huixin Sun Chen Feng Guijin Li Qingyu Zeng Cunqi Lv Jiacheng Li Qi Li Yunyan Zhang Tong Wang 《International journal of cancer. Journal international du cancer》2023,153(6):1172-1181
Information regarding the impact of the coronavirus disease 2019 (COVID-19) pandemic on cervical cancer in mainland China is lacking. We explored its impact on the hospital attendance of patients with primary cervical cancer. We included 1918 patients with primary cervical cancer who initially attended Harbin Medical University Cancer Hospital between January 23, 2019, and January 23, 2021. Attendance decreased by 31%, from 1135 in 2019 to 783 in 2020, mainly from January to June (𝜒2 = 73.362, P < .001). The percentage of patients detected by screening decreased from 12.1% in January-June 2019 to 5.8% in January-June 2020 (𝜒2 = 7.187, P = .007). Patients with stage I accounted for 28.4% in 2020 significantly lower than 36.6% in 2019 (𝜒2 = 14.085, P < .001), and patients with stage III accounted for 27.1% in 2020 significantly higher than 20.5% in 2019 (𝜒2 = 11.145, P < .001). Waiting time for treatment was extended from 8 days (median) in January-June and July-December 2019 to 16 days in January-June (𝜒2 = 74.674, P < .001) and 12 days in July-December 2020 (𝜒2 = 37.916, P < .001). Of the 179 patients who delayed treatment, 164 (91.6%) were for the reasons of the healthcare providers. Compared to 2019, the number of patients in Harbin or non-Harbin in Heilongjiang Province and outside the province decreased, and cross-regional medical treatment has been hindered. The COVID-19 pandemic has negatively impacted cervical cancer patient attendance at the initial phase. These results are solid evidence that a strategy and mechanism for the effective attendance of cervical cancer patients in response to public health emergencies is urgently needed. 相似文献
2.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):327-334.e2
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone. 相似文献
3.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
4.
Hyun Cheol Chung MD PhD Yoon-Koo Kang MD PhD Zhendong Chen MD Yuxian Bai MD Wan Zamaniah Wan Ishak MD Byoung Yong Shim MD Young Lee Park MD Dong-Hoe Koo MD PhD Jianwei Lu MD Jianming Xu MD Hong Jae Chon MD Li-Yuan Bai MD Shan Zeng MD Ying Yuan MD Yen-Yang Chen MD Kangsheng Gu MD Wen Yan Zhong PhD Shu Kuang MD Chie-Schin Shih MD Shu-Kui Qin MD PhD 《Cancer》2022,128(5):995-1003
5.
6.
8.
《Pancreatology》2022,22(2):270-276
Backgroundand purpose: Zinc is an essential element for human health and plays an important role in metabolic, immunological and other biological processes. The present study was conducted to investigate the association between zinc deficiency (ZD) and the perioperative clinical course in patients with pancreatic ductal adenocarcinoma (PDAC).MethodsOf 216 patients with PDAC who underwent elective pancreatectomy between 2013 and 2017 at our institution, 206 patients with sufficient clinical data were retrospectively reviewed. The perioperative variables were compared and the risk factors associated with infectious complications were identified.ResultsZD was preoperatively present in 36 (17.5%) of 206 patients with PDAC. In the patients of the ZD group, a higher proportion of males, higher preoperative modified Glasgow prognostic scores, a higher neutrophil-to-lymphocyte ratio, and a higher occurrence of postoperative infectious complications after pancreatectomy were observed, compared to the non-ZD group. By a univariate analysis, three risk factors were significantly associated with infectious complications after pancreatectomy: ZD (vs non-ZD: p = 0.002), serum albumin <3.5 g/dl (vs ≥ 3.5 g/dl: p = 0.005), and the procedure of pancreaticoduodenectomy (vs others: p = 0.013). By multivariate logistic regression analysis, the occurrence of infectious complications was significantly associated with ZD (OR 3.430, 95%CI 1.570 to 7.490, p = 0.002) and the procedure of pancreaticoduodenectomy (OR 2.030, 95%CI 1.090 to 3.770, p = 0.025).ConclusionsThe current study newly demonstrated that ZD could serve as a preoperative predictor of infectious complications after pancreatectomies in the patients with PDAC. 相似文献
9.
《International journal of hygiene and environmental health》2019,222(6):945-954
BackgroundPrenatal exposure to perfluoroalkyl substances (PFASs) has been associated with impaired immune and respiratory health during childhood but the evidence is inconsistent and limited for lung function. We studied the association between prenatal PFASs exposure and immune and respiratory health, including lung function, up to age 7 years in the Spanish INMA birth cohort study.MethodsWe assessed four PFASs in maternal plasma samples collected during the 1st trimester of pregnancy (years: 2003–2008): perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), and perfluorononanoate (PFNA). Mothers reported the occurrence (yes/no) of lower respiratory tract infections, wheezing, asthma, and eczema in the previous 12 months at 1.5 and 4 years of the child (n = 1188) and at 7 years (n = 1071). At ages 4 (n = 503) and 7 (n = 992) years lung function was assessed using spirometry tests.ResultsThe most abundant PFASs were PFOS and PFOA (geometric means: 5.80 and 2.31 ng/mL, respectively). The relative risk of asthma during childhood per each doubling in PFNA concentration was 0.74 (95 CI%: 0.57, 0.96). The relative risk of eczema during childhood per every doubling in PFOS concentration was 0.86 (95 CI%: 0.75, 0.98). Higher PFOA concentrations were associated with lower forced vital capacity and lower forced expiratory volume in 1 s z-scores at 4 years [β (95 CI %): −0.17 (−0.34, −0.01) and −0.13 (−0.29, 0.03), respectively], but not at 7 years.ConclusionThis longitudinal study suggests that different PFASs may affect the developing immune and respiratory systems differently. Prenatal exposure to PFNA and PFOS may be associated with reduced risk of respiratory and immune outcomes, particularly asthma and eczema whereas exposure to PFOA may be associated with reduced lung function in young children. These mixed results need to be replicated in follow-up studies at later ages. 相似文献
10.